Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Novavax, Inc.NASDAQ: NVAX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 163.28M shares rose 1.4% year over year, behind the +3.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +27.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.4% toward the trailing-twelve-month pace of +3.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
163.28M+0.8% QoQ
Last fiscal yearDec 2025
161.99M+6.4% YoY
LTMMar 2026
162.41M+3.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.4%——
1 year+6.4%——
3-year CAGR+27.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
161.99M USD
Year-over-year change
+6.4%
4-year CAGR
+21.5%

Weighted Avg Shares vs competitors

How NVAX compares with its peers on the latest reported figures

  • NVAX's LTM Mar 2026 weighted avg shares of 162.41M shares is the 4th highest of the 8 companies compared; the peer median is 139.07M shares.
  • Its year-over-year change of +3.2% is the 4th highest of 8, against a peer median of +3.0%.
  • Over three fiscal years its annual growth of +27.5% compares with a peer median of +2.2%.
NVAX Competitors Peer median
Weighted Avg Shares for NVAX and competitors
Company Period LTM YoY 3-year CAGR
MRNAModerna, Inc.LTM Sep 2026396M +2.3%-0.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
BNTXBioNTech SELTM Jun 2026247.64M +3.0%-0.2%
NVAXNovavax, Inc.LTM Mar 2026162.41M +3.2%+27.5%
PCVXVaxcyte, Inc.LTM Jun 2026139.07M +7.3%+28.0%
VALNValneva SELTM Mar 202683.89M +18.5%+13.4%
EBSEmergent BioSolutions Inc.LTM Mar 202652.93M -1.2%+2.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
Peer median (excluding NVAX) 139.07M+3.0%+2.2%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue197.58M1.6B556.38M682.16M1.12B
Cost of Revenue0902.64M343.77M202.74M71.14M
Gross Profit197.58M696.31M212.61M479.42M1.05B
Gross Margin100.0%43.5%38.2%70.3%93.7%
Research & Development2.53B1.24B737.5M391.17M336.82M
Selling, General & Admin298.36M488.69M468.95M337.19M150.35M
Operating Expenses1.88B1.34B779.13M728.35M489.07M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
EBITDA(1.68B)(604.71M)(487.39M)(108.04M)492.33M
EBITDA Margin-850.7%-37.8%-87.6%-15.8%43.8%
Operating Income(1.69B)(644.74M)(566.51M)(248.93M)563.27M
Operating Margin-853.6%-40.3%-101.8%-36.5%50.1%
Interest Income00000
Interest Expense21.13M19.88M14.42M20.08M22.55M
Other Income / Expenses(27.96M)(8.91M)23.48M72.32M(121.1M)
Income Before Tax(1.71B)(653.65M)(543.03M)(176.62M)442.17M
Pre-Tax Margin-867.8%-40.9%-97.6%-25.9%39.4%
Income Tax Expense29.22M4.29M2.03M10.88M1.87M
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Net Margin-882.5%-41.1%-98.0%-27.5%39.2%
EPS (Basic)(23.44)(8.42)(5.41)(1.23)2.72
EPS (Diluted)(23.44)(8.42)(5.41)(1.23)2.54
Weighted Avg Shares74.4M78.18M100.77M152.19M161.99M
Weighted Avg Shares (Diluted)74.4M78.18M100.77M152.19M173.1M

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.